Want to create an interactive transcript for this episode?
Podcast: Relentless Health Value
Episode: Episode 111: Costly Breakthroughs in Oncology and How Payers Will Adapt with David Guy from Aventria Health Group
Description: Currently SVP of Oncology and Specialty Market Programs at Aventria Health Group. Formerly was  CCO at Favrille, VP Strategic Marketing at Schering AG and Head of Oncology Marketing at Genentech; was instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan 00:00 New Oncology Breakthroughs. 02:35 Extending survival time to stabilizing curves that could extend to future cures. 03:50 The average cost of a new Oncology product is more than $100,000 for annual cost of treatment. 04:15 "The question is how, as a Health System, we're going to be able to manage that." 04:30 What Payers are doing to af...